PCV chemotherapy for recurrent glioblastoma multiforme.
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status > or = 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.
Kappelle
A C
AC
Departments of Neurology and Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Postma
T J
TJ
Taphoorn
M J
MJ
Groeneveld
G J
GJ
van den Bent
M J
MJ
van Groeningen
C J
CJ
Zonnenberg
B A
BA
Sneeuw
K C
KC
Heimans
J J
JJ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011344:Procarbazine / Q000008:administration & dosage* / Q000633:toxicity; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage* / Q000633:toxicity
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine